Alzheimer's Disease

The U.S. Food and Drug Administration has officially cleared a blood test for Alzheimer’s disease developed by Roche and Eli Lilly. The test can accurately identify biomarkers of Alzheimer’s through a simple blood sample, eliminating the need for expensive brain scans or invasive cerebrospinal fluid tests. This milestone approval will significantly lower the threshold for early diagnosis, enabling millions of high-risk individuals to receive timely intervention.

Scientists discover that blocking or boosting a single key protein can help the brain fight Alzheimer’s disease, successfully restoring memory and learning abilities in mice with advanced Alzheimer’s, opening a new direction for treatment.

Researchers at Cold Spring Harbor Laboratory discover that blocking the PTP1B protein improves learning and memory in an Alzheimer’s mouse model, while helping brain immune cells clear harmful amyloid-β plaques.